Leading Professional Society for Computational Biology and Bioinformatics
Connecting, Training, Empowering, Worldwide

UPCOMING DEADLINES & NOTICES

  • Registration deadline for organisers and speakers
    ECCB 2024
    April 30, 2024
  • Last day to upload ANY/ALL files to the virtual Platform
    GLBIO 2024
    May 06, 2024
  • Acceptance notification for talks and posters
    ECCB 2024
    May 08, 2024
  • Tech track proposal deadline (closes earlier if capacity is reached)
    ISMB 2024
    May 10, 2024
  • Early bird registration opens
    APBJC 2024
    May 10, 2024
  • Talk and/or poster acceptance notifications
    ISMB 2024
    May 13, 2024
  • Conference fellowship invitations sent for early abstract accepted talks and posters
    ISMB 2024
    May 13, 2024
  • (Conditional) Acceptance notification for proceedings
    ECCB 2024
    May 15, 2024
  • Registration deadline for talk presenting authors
    ECCB 2024
    May 15, 2024
  • CAMDA extended abstracts deadline
    ISMB 2024
    May 20, 2024
  • Late poster submissions deadline
    ISMB 2024
    May 20, 2024
  • Conference fellowship application deadline
    ISMB 2024
    May 20, 2024
  • Revised paper deadline
    ECCB 2024
    May 25, 2024
  • Tech track acceptance notification
    ISMB 2024
    May 31, 2024
  • Last day for discounted student hotel booking
    ISMB 2024
    May 27, 2024
  • Late poster acceptance notifications
    ISMB 2024
    May 28, 2024
  • CAMDA acceptance notification
    ISMB 2024
    May 30, 2024
  • Complete workshop/tutorial programme with speakers and schedule online
    ECCB 2024
    May 30, 2024
  • Conference fellowship acceptance notification
    ISMB 2024
    May 31, 2024
  • Tech track presentation schedule posted
    ISMB 2024
    May 31, 2024
  • Final acceptance notification for proceedings
    ECCB 2024
    May 31, 2024

Upcoming Conferences

A Global Community

  • ISCB Student Council

    dedicated to facilitating development for students and young researchers

  • Affiliated Groups

    The ISCB Affiliates program is designed to forge links between ISCB and regional non-profit membership groups, centers, institutes and networks that involve researchers from various institutions and/or organizations within a defined geographic region involved in the advancement of bioinformatics. Such groups have regular meetings either in person or online, and an organizing body in the form of a board of directors or steering committee. If you are interested in affiliating your regional membership group, center, institute or network with ISCB, please review these guidelines (.pdf) and send your exploratory questions to Diane E. Kovats, ISCB Chief Executive Officer (This email address is being protected from spambots. You need JavaScript enabled to view it.).  For information about the Affilliates Committee click here.

  • Communities of Special Interest

    Topically-focused collaborative communities

  • ISCB Member Directory

    Connect with ISCB worldwide

  • Green ISCB

    Environmental Sustainability Effort

  • Equity, Diversity, and Inclusion

    ISCB is committed to creating a safe, inclusive, and equal environment for everyone

Professional Development, Training, and Education

ISCBintel and Achievements







FASEB News - March 31, 2010

Contact: Cody Mooneyhan
This email address is being protected from spambots. You need JavaScript enabled to view it.
301-634-7104
Federation of American Societies for Experimental Biology

Making the Blind See: Gene therapy Restores Vision in Mice

New research in the FASEB Journal shows that nucleic acid nanoparticle platform delivery technology achieves successful gene transfer and reverses affects of retinitis pigmentosa in mice

Take a look at this: Scientists from Buffalo, Cleveland, and Oklahoma City made a huge step toward making the blind see, and they did it by using a form of gene therapy that does not involve the use of modified viruses. In a research report published in the April 2010 print issue of The FASEB Journal (www.fasebj.org), scientists describe how they used a non-viral, synthetic nanoparticle carrier to improve and save the sight of mice with retinitis pigmentosa, an inherited disease characterized by progressive vision loss and eventual blindness.

"We hope the results of our study will be instrumental in generating a cure for the debilitating blindness associated with retinitis pigmentosa and other inherited and acquired retinal diseases," said Muna I. Naash, Ph.D., a researcher involved in the work from the Department of Cell Biology at the University of Oklahoma Health Sciences Center in Oklahoma City. "Compacted DNA nanoparticles are an exciting treatment strategy for these diseases and we look forward to exciting new developments."

To make this discovery, Naash and colleagues used groups of mice with the retinal degeneration slow (Rds) gene, which causes retinitis pigmentosa. The mice received one of three types of "treatments:" nanoparticles containing the normal copy of the Rds gene, the normal gene alone, or saline solution. After these treatments were delivered to the mice, the structure and function of the retina were analyzed by comparing them to untreated mice with retinitis pigmentosa and healthy mice with the normal Rds gene. Researchers also measured the level and pattern of Rds gene expression, as well as functional, structural and biochemical improvements in disease symptoms. They discovered that mice receiving the nanoparticle gene therapy show significant signs of healing. These mice had structural improvement in their retinas, as well as functional vision improvements, which lasted throughout the duration of the study. The mice that received the gene alone or saline continued to lose their vision. The nanoparticles were safe and well-tolerated with no adverse effects.

"Making the blind see was once called a miracle," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. "As we have expanded our understanding of evolution, genetics, and nanotechnology, chances are that "miraculous" cures will become as commonplace as those claimed by faith-healers past and present."

According to the National Institutes of Health Office of Rare Diseases Research, retinitis pigmentosa is a group of inherited eye diseases that affect the retina. Retinitis pigmentosa causes cells in the retina to die prematurely, eventually leading to vision loss. There is no cure.

###

Receive monthly highlights from The FASEB Journal by e-mail. Sign up at www.faseb.org/fjupdate.aspx. The FASEB Journal (www.fasebj.org) is published by the Federation of the American Societies for Experimental Biology (FASEB). The journal has been recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century and is the most cited biology journal worldwide according to the Institute for Scientific Information.

FASEB comprises 23 societies with more than 90,000 members, making it the largest coalition of biomedical research associations in the United States. FASEB enhances the ability of scientists and engineers to improve—through their research—the health, well-being and productivity of all people. FASEB's mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.

Details: Xue Cai, Shannon M. Conley, Zack Nash, Steven J. Fliesler, Mark J. Cooper, and Muna I. Naash. Gene delivery to mitotic and postmitotic photoreceptors via compacted DNA nanoparticles results in improved phenotype in a mouse model of retinitis pigmentosa. FASEB J. 2010 24: 1178-1191. DOI: 10.1096/fj.09-139147; www.fasebj.org/cgi/content/abstract/24/4/1178

Exclusively for members

  • Member Discount

    ISCB Members enjoy discounts on conference registration (up to $150), journal subscriptions, book (25% off), and job center postings (free).

  • Why Belong

    Connecting, Collaborating, Training, the Lifeblood of Science. ISCB, the professional society for computational biology!

     

Supporting ISCB

Donate and Make a Difference

Giving never felt so good! Considering donating today.